Compass Therapeutics announces first-in-human Phase 1 trial of CTX-471
Category: #health  By Saipriya Iyer  Date: 2019-07-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Compass Therapeutics announces first-in-human Phase 1 trial of CTX-471

CTX-471 has shown promising preclinical data, which include total eradication of established tumors in syngeneic mouse models.

Compass Therapeutics, a clinical-stage biopharmaceutical firm targeting human immune synapse with novel monoclonal and multi-specific antibody therapeutics, has recently announced the commencement of its first-in-human, open-label, multi-center Phase 1 trial of CTX-471.

For the uninitiated, CTX-471 is a fully human monoclonal antibody that binds and triggers a unique epitope of the co-stimulatory receptor CD137 expressed on NK cells and T cells.

Sources close to the pilot claim that patient enrollment in the trial is open to subjects with metastatic or locally advanced solid cancers that are developed while receiving an approved PD-L1 or PD-1 inhibitor for a minimum period of three months.

F. Stephen Hodi, MD, Director of the Melanoma Center, The Center for Immuno-Oncology at Dana-Farber/Brigham, and Women’s Cancer Center, said that the field of oncology is in immense need for novel ways that enable the immune system to fight cancer beyond PD-1/PD-L1 checkpoint inhibitors. He said they currently own very limited options to treat patients in whom PD-L1 or PD-1 inhibitors has failed.

Source cite that the multiple ascending dose (MAD) study has the potential for a dose expansion phase. The primary objective of MAD study is to assess the tolerability and safety of CTX-471 monotherapy at various doses.

The dose expansion stage will evaluate a larger cohort of patients to determine an optimized dose for future Phase 2 studies. Moreover, the secondary endpoints will include measures of overall response rate and progression- free survival, among others.

Speaking on the trial, Thomas Schuetz, MD, PhD, Scientific founder & CEO, Compass Therapeutics, said the company is delighted to have reached this milestone to begin testing its treatment on patients.

He said that their firm expects CTX-471 to be a best-in-class CD137 agonist due to its promising preclinical data, which include total eradication of established tumors in syngeneic mouse models and development of long-term, functional immunological memory in these models.

Source Credit: https://www.compasstherapeutics.com/press-releases/compass-therapeutics-announces-first-patient-dosed-in-phase-1-trial-of-ctx-471/



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Tetra Pak announces target to reach net-zero GHG emissions by 2030
Tetra Pak announces target to reach net-zero GHG emissions by 2030
By Saipriya Iyer

Tetra Pak, a food processing and packaging solutions provider, has recently announced its target to reach net-zero GHG (greenhouse gas) emissions in its operations by 2030.

The targ...

DTE Energy pledges to reach net-zero emissions of GHG by 2050
DTE Energy pledges to reach net-zero emissions of GHG by 2050
By Saipriya Iyer

DTE Energy has reportedly pledged to reach the net-zero GHG (greenhouse gas) emissions by 2050. This can be ensured through various actions involving customers, suppliers, and its infrastructure, that align with the lo...

Researchers investigate a novel treatment for Childhood Alzheimer’s
Researchers investigate a novel treatment for Childhood Alzheimer’s
By Saipriya Iyer

Researchers at the Lundquist Institute have reportedly collaborated with the Cure Sanfilippo Foundation on a new clinical trial to investigate if repurposing an anti-inflammatory drug could provide relief to children t...